No Effect of Hepatic Impairment on the Pharmacokinetics of Serelaxin, a Recombinant Human Relaxin-2 in Development for the Treatment of Acute Heart Failure

Authors

Kobalava Z. ¹ , Halabi A. ² , Zahringer A. ³ , Pang Y. ⁴ , Dahlke M. ⁵

Journal

Publisher

Lippincott Williams & Wilkins

Issue number

Language

English

State

Published

Volume

128

Year

2013

Organizations

¹ Peoples Friendship Univ Russia, Dept Internal Dis Cardiol & Clin Pharmacol, Moscow, Russia
² Kiel GmbH, Clin Rsch Serv, CRS, Kiel, Germany
³ Novartis Pharma AG, NIBR, Basel, Switzerland
⁴ Novartis Inst BioMed Rsch, Cambridge, MA USA
⁵ Novartis Pharma AG, Translat Med, Basel, Switzerland

Keywords

Acute heart failure; Pharmacokinetics; Drugs

Cite

Article

Skubachevskii A.L.

Proceedings of the Steklov Institute of Mathematics. Vol. 283. 2013. P.. 197-225

Article

Subotyalov M., Druzhinin V., Sorokina T.S.

Journal of Nephrology. Vol. 26. 2013.